Adjuvant anti-PD-1 therapy improves melanoma-specific survival in stage IIIC-IV melanoma patients with high tumor mutation burden and BRAF V600 mutation

Adjuvant anti-PD-1 therapy improves melanoma-specific survival in stage IIIC-IV melanoma patients with high tumor mutation burden and BRAF V600 mutation

Immune checkpoint inhibitors (ICI) have significantly improved melanoma-specific survival (MSS), particularly in patients with tumors with a high tumor mutational burden (TMB) or BRAF mutation. In the adjuvant setting, ICIs significantly improve relapse-free survival (RFS), but data on MSS are still...

Full description

Saved in:
Bibliographic Details
Main Authors: Julia Forschner, Julia Huynh, Christopher Schroeder, Sorin Armeanu-Ebinger, Olga Seibel-Kelemen, Axel Gschwind, Irina Bonzheim, Thomas K. Eigentler, Teresa Amaral, Stephan Ossowski, Lukas Flatz, Claus Garbe, Andrea Forschner, Markus Reitmajer
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-08-01
Series:Frontiers in Oncology
Subjects:
adjuvant immune checkpoint inhibitors
relapse-free survival
melanoma-specific survival
tumor mutational burden
BRAF V600E/K mutation
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1618596/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items